114 results on '"Su, Kang-Yi"'
Search Results
102. Rutin, a Flavonoid That Is a Main Component ofSaussurea involucrata, Attenuates the Senescence Effect in D-Galactose Aging Mouse Model
- Author
-
Yang, Ying-Chen, primary, Lin, Hsueh-Yi, additional, Su, Kang-Yi, additional, Chen, Chien-Hsu, additional, Yu, Yung-Lung, additional, Lin, Chai-Ching, additional, Yu, Sung-Liang, additional, Yan, Hong-Young, additional, Su, Kuo-Jung, additional, and Chen, Yi-Lin Sophia, additional
- Published
- 2012
- Full Text
- View/download PDF
103. Clustered Genomic Alterations in Chromosome 7p Dictate Outcomes and Targeted Treatment Responses of Lung Adenocarcinoma With EGFR-Activating Mutations
- Author
-
Yuan, Shinsheng, primary, Yu, Sung-Liang, additional, Chen, Hsuan-Yu, additional, Hsu, Yi-Chiung, additional, Su, Kang-Yi, additional, Chen, Huei-Wen, additional, Chen, Chih-Yi, additional, Yu, Chong-Jen, additional, Shih, Jin-Yuan, additional, Chang, Yih-Leong, additional, Cheng, Chiou-Ling, additional, Hsu, Chung-Ping, additional, Hsia, Jiun-Yi, additional, Lin, Chien-Yu, additional, Wu, Guani, additional, Liu, Chia-Hsin, additional, Wang, Chin-Di, additional, Yang, Kang-Chung, additional, Chen, Yi-Wei, additional, Lai, Yi-Ling, additional, Hsu, Chu-Chun, additional, Lin, Tai-Ching, additional, Yang, Tsung-Ying, additional, Chen, Kun-Cheieh, additional, Hsu, Kuo-Hsuan, additional, Chen, Jeremy J.W., additional, Chang, Gee-Chen, additional, Li, Ker-Chau, additional, and Yang, Pan-Chyr, additional
- Published
- 2011
- Full Text
- View/download PDF
104. Abstract 5238: Lung adenocarcinoma harboring EGFR L858R mutation has increased invasive ability through up-regulation of CXCR4
- Author
-
Chang, Tzu-Hua, primary, Yang, Hsiao-Yin, additional, Tsai, Meng-Feng, additional, Su, Kang-Yi, additional, Yang, Pan-Chyr, additional, and Shih, Jin-Yuan, additional
- Published
- 2011
- Full Text
- View/download PDF
105. Enterovirus-Induced miR-141 Contributes to Shutoff of Host Protein Translation by Targeting the Translation Initiation Factor eIF4E
- Author
-
Ho, Bing-Ching, primary, Yu, Sung-Liang, additional, Chen, Jeremy J.W., additional, Chang, Sui-Yuan, additional, Yan, Bo-Shiun, additional, Hong, Qi-Sheng, additional, Singh, Sher, additional, Kao, Chuan-Liang, additional, Chen, Hsuan-Yu, additional, Su, Kang-Yi, additional, Li, Ker-Chau, additional, Cheng, Chiou-Ling, additional, Cheng, Hao-Wei, additional, Lee, Jen-Yi, additional, Lee, Chun-Nan, additional, and Yang, Pan-Chyr, additional
- Published
- 2011
- Full Text
- View/download PDF
106. Shisa3 Is Associated with Prolonged Survival through Promoting [beta]-Catenin Degradation in Lung Cancer.
- Author
-
Chen, Chun-Chieh, Chen, Hsuan-Yu, Su, Kang-Yi, Hong, Qi-Sheng, Yan, Bo-Shiun, Chen, Ching-Hsien, Pan, Szu-Hua, Chang, Yih-Leong, Wang, Chia-Jen, Hung, Pei-Fang, Yuan, Shinsheng, Chang, Gee-Chen, Chen, Jeremy J W, Yang, Pan-Chyr, Yang, Ya-Chien, and Yu, Sung-Liang
- Abstract
RATIONALE: Despite advances in treatment and prognosis of non-small cell lung cancer (NSCLC), patient outcomes are still unsatisfactory. OBJECTIVES: To reduce the morbidity and mortality of patients with NSCLC, a more comprehensive understanding of mechanisms involved in cancer progression is urgently needed. METHODS: By comparison of gene expression profiles in the cell line pair with differential invasion ability, CL1-0 and CL1-5, we found that Shisa3 was highly expressed in the low invasive cells. The effect of Shisa3 on invasion, migration, proliferation, apoptosis, epithelial-mesenchymal transition, and anchorage-independent growth activities in vitro and on tumor growth and metastasis in mice models were examined. The underlying mechanism of Shisa3 was explored by microarray and pathway analysis. Finally, the correlation of Shisa3 expression and clinical outcome was also calculated. MEASUREMENTS AND MAIN RESULTS: We identified Shisa3 as a novel tumor suppressor, which induces [beta]-catenin degradation resulting in suppression of tumorigenesis and invasion in vitro. Shisa3 decreased the tumor growth in mice with subcutaneous implantation and reduced the number of metastatic nodules in mice with tail vein injection and orthotopic implantation. Shisa3 performs the tumor suppression activity through WNT signaling predicted by microarray analysis. Our data found that Shisa3 accelerates [beta]-catenin degradation and was positively associated with overall survival and progression-free survival of NSCLC. CONCLUSIONS: Our results reveal that Shisa3 acts as a tumor suppressor by acceleration of [beta]-catenin degradation and provide new insight for cancer prognosis and therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
107. Tissue Proteogenomic Landscape Reveals the Role of Uncharacterized SEL1L3 in Progression and Immunotherapy Response in Lung Adenocarcinoma
- Author
-
Shen, Chi-Ya, Chang, Wen-Hsin, Chen, Yi-Ju, Weng, Chia-Wei, Regmi, Prabha, Kier, Mickiela K. K., Su, Kang-Yi, Chang, Gee-Chen, Chen, Jin-Shing, Chen, Yu-Ju, and Yu, Sung-Liang
- Abstract
The fundamental pursuit to complete the human proteome atlas and the unmet clinical needs in lung adenocarcinoma have prompted us to study the functional role of uncharacterized proteins and explore their implications in cancer biology. In this study, we characterized SEL1L3, a previously uncharacterized protein encoded from chromosome 4 as a dysregulated protein in lung adenocarcinoma from the large-scale tissue proteogenomics data set established using the cohort of Taiwan Cancer Moonshot. SEL1L3 was expressed in abundance in the tumor parts compared with paired adjacent normal tissues in 90% of the lung adenocarcinoma patients in our cohorts. Moreover, survival analysis revealed the association of SEL1L3 with better clinical outcomes. Intriguingly, silencing of SEL1L3 imposed a reduction in cell viability and activation of ER stress response pathways, indicating a role of SEL1L3 in the regulation of cell stress. Furthermore, the immune profiles of patients with higher SEL1L3 expression were corroborated with its active role in immunophenotype and favorable clinical outcomes in lung adenocarcinoma. Taken together, our study revealed that SEL1L3 might play a vital role in the regulation of cell stress, interaction with cancer cells and the immune microenvironment. Our research findings provide promising insights for further investigation of its molecular signaling network and also suggest SEL1L3 as a potential emerging adjuvant for immunotherapy in lung adenocarcinoma.
- Published
- 2022
- Full Text
- View/download PDF
108. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With KrasMutation in East Asian Populations: A Single-Center Cohort Study in the Republic of China
- Author
-
Wu, Shang-Gin, Liao, Wei-Yu, Su, Kang-Yi, Yu, Sung-Liang, Huang, Yen-Lin, Yu, Chong-Jen, Chih-Hsin Yang, James, and Shih, Jin-Yuan
- Abstract
Krasmutation is the most common driver oncogene present in patients with NSCLC. Recently, the precision medicine for patients with Kras-mutated NSCLC has been under investigation, but the best treatment is still unknown. This study aimed to analyze the clinical characteristics, immune checkpoint inhibitor (ICI) response, and prognostic factors of patients with NSCLC with different Krasmutation subtypes.
- Published
- 2021
- Full Text
- View/download PDF
109. A Lung Cancer Mouse Model Database.
- Author
-
Cai L, Gao Y, DeBerardinis RJ, Acquaah-Mensah G, Aidinis V, Beane JE, Biswal S, Chen T, Concepcion-Crisol CP, Grüner BM, Jia D, Jones R, Kurie JM, Lee MG, Lindahl P, Lissanu Y, Lorz Lopez MC, Martinelli R, Mazur PK, Mazzilli SA, Mii S, Moll H, Moorehead R, Morrisey EE, Ng SR, Oser MG, Pandiri AR, Powell CA, Ramadori G, Santos Lafuente M, Snyder E, Sotillo R, Su KY, Taki T, Taparra K, Xia Y, van Veen E, Winslow MM, Xiao G, Rudin CM, Oliver TG, Xie Y, and Minna JD
- Abstract
Lung cancer, the leading cause of cancer mortality, exhibits diverse histological subtypes and genetic complexities. Numerous preclinical mouse models have been developed to study lung cancer, but data from these models are disparate, siloed, and difficult to compare in a centralized fashion. Here we established the Lung Cancer Mouse Model Database (LCMMDB), an extensive repository of 1,354 samples from 77 transcriptomic datasets covering 974 samples from genetically engineered mouse models (GEMMs), 368 samples from carcinogen-induced models, and 12 samples from a spontaneous model. Meticulous curation and collaboration with data depositors have produced a robust and comprehensive database, enhancing the fidelity of the genetic landscape it depicts. The LCMMDB aligns 859 tumors from GEMMs with human lung cancer mutations, enabling comparative analysis and revealing a pressing need to broaden the diversity of genetic aberrations modeled in GEMMs. Accompanying this resource, we developed a web application that offers researchers intuitive tools for in-depth gene expression analysis. With standardized reprocessing of gene expression data, the LCMMDB serves as a powerful platform for cross-study comparison and lays the groundwork for future research, aiming to bridge the gap between mouse models and human lung cancer for improved translational relevance.
- Published
- 2024
- Full Text
- View/download PDF
110. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan.
- Author
-
Wu SG, Liao WY, Su KY, Yu SL, Huang YL, Yu CJ, Chih-Hsin Yang J, and Shih JY
- Abstract
Introduction: Kras mutation is the most common driver oncogene present in patients with NSCLC. Recently, the precision medicine for patients with Kras -mutated NSCLC has been under investigation, but the best treatment is still unknown. This study aimed to analyze the clinical characteristics, immune checkpoint inhibitor (ICI) response, and prognostic factors of patients with NSCLC with different Kras mutation subtypes., Methods: From 2005 to 2018, we collected nonsquamous NSCLC tissue samples for Kras mutation analysis using direct Sanger sequencing or MassARRAY genotyping (Agena Bioscience, San Diego, CA) at the National Taiwan University Hospital. Clinical characteristics, ICI treatment effectiveness, time-to-tumor recurrence (TTR), and overall survival (OS) were analyzed using multivariate Cox models, to estimate adjusted hazard ratios (HRs)., Results: Among 5278 patients with nonsquamous NSCLC, 246 (4.7%) had Kras mutations. The major Kras mutation subtypes were G12C (32.9%), G12D (23.7%), and G12V (18.9%). Patients with Kras -G12C had a higher proportion of male individuals ( p = 0.018) and smokers ( p < 0.001). Among the 25 patients treated with ICIs, patients with Kras -G12C had a higher response rate (53.8% versus 8.3%, p = 0.030) and longer progression-free survival (4.8 mo versus 2.1 mo, p = 0.028) than those with Kras -non-G12C. For the 85 patients with early-stage NSCLC, those with G12C had shorter TTR (22.8 mo) than those with Kras -non-G12C (97.7 mo, p = 0.004). For the 143 patients with advanced-stage NSCLC, there was a significant difference in OS between patients with Kras -G12C and Kras -non-G12C (7.7 mo versus 6.0 mo, p = 0.018) and patients with Kras -G12V had the shortest OS (5.2 mo). Multivariate analysis revealed association of shorter OS with Kras -G12V (HR = 2.47, p = 0.002), stage IV disease status (HR = 2.69, p = 0.008), and NSCLC-not otherwise specified histology (HR = 3.12, p = 0.002)., Conclusions: Kras -G12C was associated with favorable ICI treatment effectiveness in patients with NSCLC. Kras -G12C mutation was associated with shorter TTR in patients with early-stage NSCLC, and Kras -G12V mutation was associated with shorter OS in patients with advanced-stage NSCLC when comparing with Kras -G12C., (© 2020 The Authors.)
- Published
- 2020
- Full Text
- View/download PDF
111. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study.
- Author
-
Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, Bai YY, Huang DD, Thress KS, and Yang JC
- Subjects
- Acrylamides, Adult, Aged, Aged, 80 and over, Aniline Compounds, ErbB Receptors genetics, Female, Genomics, Humans, Male, Middle Aged, Retrospective Studies, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, ErbB Receptors antagonists & inhibitors, Lung Neoplasms drug therapy, Mutation, Piperazines therapeutic use
- Abstract
Background: Osimertinib is approved for the treatment of non-small-cell lung cancer in patients who develop the EGFR Thr790Met mutation after treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs). We assessed outcomes in patients with non-small-cell lung cancer and the EGFR Thr790Met mutation who were treated with osimertinib, a third-generation EGFR TKI, after previous treatment failure with one or more other EGFR TKIs., Methods: Eligible patients had been enrolled at one centre in the AURA study, had shown resistance to a previous EGFR TKI, and had EGFR-activating mutations and acquired Thr790Met mutation detectable in tumour tissue or plasma. Patients took 20-240 mg osimertinib per day until disease progression or development of intolerable side-effects. Plasma samples were collected every 6 weeks and tumour tissue biopsy was done at study entry and was optional after disease progression. We tested samples for resistance mechanisms, including EGFR-activating, Thr790Met, and Cys797Ser mutations, and assessed associations with overall survival, progression-free survival, and survival after disease progression., Findings: Of 71 patients enrolled in AURA, 53 were eligible for this analysis. Median progression-free survival was 11·1 months (95% CI 8·4-13·9) and overall survival was 16·9 months (11·7-29·1). 47 patients had disease progression. Median overall survival after osimertinib progression was 5·4 months (95% CI 4·1-10·0). Plasma samples were available for 40 patients after disease progression. 12 (30%) of these had the Thr790Met mutation (four of whom also had Cys797Ser mutations). Patients without detectable EGFR-activating mutations in plasma before treatment had the best overall and post-progression survival (22·4 months, 95% CI 15·6-not reached, and 10·8 months, 7·2-not reached, respectively). Loss of the Thr790Met mutation but presence of EGFR-activating mutations in plasma were associated with the shortest progression-free survival (median 2·6 months, 95% CI 1·3-not reached). In 22 post-progression tumour samples, we found one squamous cell and two small-cell transformations. We detected Thr790Met in nine (50%) of 18 samples, Cys797Ser in two (17%) of 12, cMET amplification in five (50%) of ten, BRAF mutation in one (8%) of 13, and KRAS mutation in one (8%) of 13., Interpretation: Heterogeneous resistance mechanisms developed in patients receiving osimertinib. Differences in resistance mechanisms might dictate future development strategies for osimertinib in clinical trials., Funding: AstraZeneca, Taiwan Ministry of Science and Technology., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
112. Predilection of contralateral upper lung metastasis in upper lobe lung adenocarcinoma patients.
- Author
-
Huang YH, Hsu KH, Tseng JS, Chen KC, Su KY, Chen HY, Chang CS, Chen JJ, Yu SL, Chen HW, Yang TY, and Chang GC
- Abstract
Background: Lung cancer with lung to lung metastasis is common. The objective of this study was to investigate the association among the distribution of contralateral lung metastases versus primary lung tumor location, clinical characteristics, and epidermal growth factor receptor (EGFR) mutations status., Methods: The study included treatment-naïve stage IV lung adenocarcinoma with contralateral lung metastases from 2012 through 2013., Results: In total, 103 patients were enrolled after excluding lung cancer with histology other than adenocarcinoma, synchronous multiple primary lung cancers, or other active malignancy. The median age was 65 years (range, 28-93 years); 47 male patients (45.6%); 69 non-smoker (NS) patients (67.0%); 68 Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 patients (66.0%); 38 M1a patients (38.9%); and 60 EGFR mutation patients (58.3%). There were 51 cases (49.5%) with primary lung cancer located over upper lobes. Among them, 36 (70.6%) had contralateral upper lung predominance metastasis, 9 (17.6%) had lower lung predominance, and 6 (11.8%) had equal distribution. Among the 52 lower lobe tumors, 17 (32.7%), 19 (36.5%), and 16 (30.8%) had upper, lower lung predominance, and equal distribution metastasis, respectively. Univariate analysis showed only male gender and primary tumor location over upper lobes were significantly associated with contralateral upper lung predominance metastases. After multivariate analysis, only primary tumor location over upper lobes was significantly associated with contralateral upper lung predominance metastases (adjusted OR 5.49, 95% CI, 2.15-14.03, P<0.001)., Conclusions: Upper lobe lung adenocarcinoma was significantly associated with contralateral upper lung predominance metastases. Further research is needed to elucidate the mechanisms underlying this phenomenon.
- Published
- 2016
- Full Text
- View/download PDF
113. Rutin, a Flavonoid That Is a Main Component of Saussurea involucrata, Attenuates the Senescence Effect in D-Galactose Aging Mouse Model.
- Author
-
Yang YC, Lin HY, Su KY, Chen CH, Yu YL, Lin CC, Yu SL, Yan HY, Su KJ, and Chen YL
- Abstract
Saussurea involucrata (Kar. et Kir.), known as the snow lotus, grows in the Tian Shan and A'er Tai areas of China. It has recently been reported that the ethyl acetate extract of S. involucrata (SI-2) can inhibit proliferation and induce apoptosis in PC-3 human prostate cancer cells. This study investigated the protective effect of ethyl acetate extract of S. involucrata (SI-2) or rutin, a flavonoid extracted from ethyl acetate extract of S. involucrata (SI-2), on D-galactose- (D-gal-) induced brain injury in mice. Administering SI-2 or rutin (30 mg/kg/d and 30 mg/kg/d) for 6 weeks, concomitant with D-gal injection, significantly increased superoxide dismutase and glutathione peroxidase activities and decreased the MDA level in plasma. Furthermore, the result showed that the percentages of cleaved caspase-3 and PARP in the D-gal-treated mice were much higher than those in the control. Pretreatment using SI-2 or rutin decreased the expression of cyclooxygenase-2 via downregulation of NF-kappaB, resulting in a decrease in lipid peroxidation. Furthermore, our results also showed that oral administration of rutin to these mice significantly improved behavioral performance in a step-through passive avoidance task and these results suggest that SI-2 or rutin exerts potent antiaging effects on D-gal in mice via antioxidative mechanisms.
- Published
- 2012
- Full Text
- View/download PDF
114. Mice deficient in collapsin response mediator protein-1 exhibit impaired long-term potentiation and impaired spatial learning and memory.
- Author
-
Su KY, Chien WL, Fu WM, Yu IS, Huang HP, Huang PH, Lin SR, Shih JY, Lin YL, Hsueh YP, Yang PC, and Lin SW
- Subjects
- Animals, Animals, Newborn, Brain metabolism, Disks Large Homolog 4 Protein, GAP-43 Protein metabolism, Guanylate Kinases, Hippocampus metabolism, Intracellular Signaling Peptides and Proteins metabolism, Membrane Proteins metabolism, Mice, Mice, Knockout, Nerve Tissue Proteins deficiency, Nerve Tissue Proteins metabolism, Phosphoproteins deficiency, Phosphoproteins metabolism, Swimming, Long-Term Potentiation physiology, Maze Learning physiology, Memory physiology, Nerve Tissue Proteins physiology, Phosphoproteins physiology
- Abstract
Collapsing response mediator protein-1 (CRMP-1) was initially identified in brain and has been implicated in plexin-dependent neuronal function. The high amino acid sequence identity among the five CRMPs has hindered determination of the functions of each individual CRMP. We generated viable and fertile CRMP-1 knock-out (CRMP-1(-/-)) mice with no evidence of gross abnormality in the major organs. CRMP-1(-/-) mice exhibited intense microtubule-associated protein 2 (MAP2) staining in the proximal portion of the dendrites, but reduced and disorganized MAP2 staining in the distal dendrites of hippocampal CA1 pyramidal cells. Immunoreactivity to GAP-43 (growth-associated protein-43) and PSD95 (postsynaptic density-95) (a postsynaptic membrane adherent cytoskeletal protein) was also decreased in the CA1 region of the knock-out mice. These changes were consistent with the mutant mice showing a reduction in long-term potentiation (LTP) in the CA1 region and impaired performance in hippocampal-dependent spatial learning and memory tests. CRMP-1(-/-) mice showed a normal synapsin I labeling pattern in CA1 and normal paired-pulse facilitation. These findings provide the first evidence suggesting that CRMP-1 may be involved in proper neurite outgrowth in the adult hippocampus and that loss of CRMP-1 may affect LTP maintenance and spatial learning and memory.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.